Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10442810
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Patent number: 10442789
    Abstract: Provided herein are modified amino acids comprising a tetrazine groups according to Formula I: polypeptides, antibodies, payloads and conjugates comprising these modified amino acid residues derived from the modified amino acids, and methods of producing the polypeptides, antibodies, payloads and conjugates comprising the modified amino acid residues. The polypeptides, antibodies, payloads and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: October 15, 2019
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Wenjin Yang, Qun Yin
  • Patent number: 10435408
    Abstract: Azepine derivatives acting on 5-HT7 receptors and pharmaceutically acceptable salts thereof are disclosed. The azepine derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for and high antagonistic activities on 5-HT7 receptors. Due to these advantages, the azepine derivatives and the pharmaceutically acceptable salts thereof can be applied to therapeutic or prophylactic agents for central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, biorhythm dysregulation, sleep disturbance, and smooth muscle diseases where 5-HT7 receptors antagonistic activity is required.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: October 8, 2019
    Assignee: Korea Institute of Science and Technology
    Inventors: Hyunah Choo, Youngjae Kim, Jihye Seong, Ghil Soo Nam, Yong Seo Cho
  • Patent number: 10435418
    Abstract: A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an ?-effect amine in aqueous solution at a temperature between about ?5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a boron compound having a boron atom bonded to a sp2 hybridized carbon conjugated with a cis-carbonyl, the boron having at least one labile substituent, with an ?-effect amine, in a solvent for a time sufficient to form an adduct, which may proceed to further products.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 8, 2019
    Assignee: The Research Foundation for the State University o
    Inventors: Susan Bane Tuttle, Ozlem Dilek, Kamalika Mukherjee
  • Patent number: 10431748
    Abstract: The present specification relates to a cyclic compound and an organic light emitting device comprising the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 1, 2019
    Assignee: LG CHEM, LTD.
    Inventors: Dong Uk Heo, Dong Hoon Lee, Jungoh Huh, Boonjae Jang, Minyoung Kang, Miyeon Han
  • Patent number: 10421747
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 24, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Wim Vermeulen, Steven Anna Hostyn, Filip Albert Celine Cuyckens, Russell Mark Jones, Diego Fernando Domenico Broggini
  • Patent number: 10421744
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: September 24, 2019
    Assignee: PFIZER INC.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Patent number: 10414721
    Abstract: Provided is a highly potent and selective endocannabioid cellular reuptake inhibitor represented by formula (I): or a pharmaceutically acceptable solvate or co-crystal thereof as well as to a formulation comprising this inhibitor, and to methods of treatment in which this inhibitor is used.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 17, 2019
    Assignee: UNIVERSITY OF BERN
    Inventors: Andrea Chicca, Jurg Gertsch
  • Patent number: 10399951
    Abstract: The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 3, 2019
    Assignee: FORMA THERAPEUTICS, INC.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Patent number: 10383960
    Abstract: Disclosed herein are isotopically labeled calcofluor derivatives and uses of such to detect fungi, such as filamentous fungi, including Aspergillus species, such as by positron emission tomography (PET) scanning.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 20, 2019
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The Research Foundation of the State Univeristy of New York
    Inventors: Peter R. Williamson, Dale O. Kiesewetter, John Panepinto, Jin Qiu
  • Patent number: 10385043
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: August 20, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventor: Cyrille Lescop
  • Patent number: 10385076
    Abstract: A surface treatment agent including a compound (?) is provided. The compound (?) has one or more M-OH groups and/or groups capable of forming M-OH (wherein M represents a metal atom), an amino group and a triazine ring; wherein said amino group is bonded to a terminal; one or more said amino groups bonded to the terminal are present; and one or more said triazine rings are present.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 20, 2019
    Assignees: Sulfur Chemical Laboratory, Inc., Meiko Electronics Co., Ltd.
    Inventors: Kunio Mori, Yusuke Matsuno, Katsuhito Mori, Takahiro Kudo, Shuukichi Takii, Shigeru Michiwaki, Manabu Miyawaki, Masanori Yanai, Kouichi Kamiyama, Hitomi Chiba, Yasuyuki Masuda
  • Patent number: 10376517
    Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: August 13, 2019
    Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.
    Inventors: Rebecca Taub, Charles H. Reynolds, Lianhe Shu, Ping Wang, Duk Soon Choi
  • Patent number: 10377747
    Abstract: The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: August 13, 2019
    Assignee: Wuxi Shuangliang Biotechnology Co., Ltd.
    Inventors: Jiaquan Wu, Haijun Zhang, Huanyan Cao, Shenshuang Jin, Shuai Zhang, Zhenghua Lu, Jian Dong, Chengchen Wang, Qiu Tan
  • Patent number: 10376594
    Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 13, 2019
    Assignee: TAGWORKS PHARMACEUTICALS B.V.
    Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
  • Patent number: 10377944
    Abstract: Surface-modified nanoparticles are produced by associating ligand interactive agents with the surface of a nanoparticle. The ligand interactive agents are bound to surface modifying ligands that are tailored to impart particular solubility and/or compatibility properties. The ligand interactive agents are crosslinked via a linking/crosslinking agent, such as hexamethoxymethylmelamine or a derivative thereof. The linking/crosslinking agent may provide a binding site for binding the surface modifying ligands to the ligand interactive agents.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: August 13, 2019
    Assignee: Nanoco Technologies Ltd.
    Inventor: Imad Naasani
  • Patent number: 10370372
    Abstract: To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: August 6, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa Minamiguchi, Shigeo Okajima, Takahiro Asai, Masanori Asai, Yoshio Ogino
  • Patent number: 10370342
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 6, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Patent number: 10363261
    Abstract: Provided herein are compounds of the formula (I) wherein the variables R1, R2, R3, R4, X1, X2, Y1, and A1 are as defined herein. Such compounds may be used, for example, for the inhibition of enolase enzymes, including preferential inhibition of one isoenzyme of over one or more of the other isoenzymes. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: July 30, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Florian Muller, David S. Maxwell, William G. Bornmann, Yu-Hsi Lin, Basvoju A. Bhanu Prasad, Zhenghong Peng, Duoli Sun, Nikunj Satani, M. Emilia Di Francesco, Ronald A. Depinho, Barbara Czako, Federica Pisaneschi
  • Patent number: 10358437
    Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 23, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor